About Lifecore Biomedical Inc.
Ticker
info
LFCR
Trading on
info
NASDAQ
ISIN
info
US5147661046
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
Paul Josephs
Headquarters
info
3515 Lyman Boulevard, Chaska, MN, United States, 55318
Employees
info
382
Website
info
lifecore.com
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Metrics
BasicAdvanced
Market cap
info
$180M
P/E ratio
info
-
EPS
info
-$1.27
Dividend Yield
info
0.00%
Beta
info
1.08
Forward P/E ratio
info
8.67
EBIDTA
info
$8.2M
Ex dividend date
info
-
Price & volume
Market cap
info
$180M
Average daily volume
info
0.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
8.67
PEG ratio
info
2.66
Trailing P/E
info
0
Price to sales
info
1.39
Price to book
info
197.99
Earnings
EPS
info
-$1.27
EPS estimate (current quarter)
info
-$0.16
EPS estimate (next quarter)
info
-$0.21
EBITDA
info
$8.2M
Revenues (TTM)
info
$129M
Revenues per share (TTM)
info
$3.46
Technicals
Beta
info
1.08
52-week High
info
$8.98
52-week Low
info
$3.63
50-day moving average
info
$5.12
200-day moving average
info
$6.92
Short ratio
info
4.34
Short %
info
8.71%
Management effectiveness
ROE (TTM)
info
-76.41%
ROA (TTM)
info
-3.04%
Profit margin
info
-23.78%
Gross profit margin
info
$40.6M
Operating margin
info
-13.25%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-3.80%
Share stats
Outstanding Shares
info
37.5M
Float
info
19.8M
Insiders %
info
2.38%
Institutions %
info
77.39%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 3 analysts.

Average price target

info
$6.67
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.06
-$0.04
-71.43%
Q2 • 25Missed
-$0.29
-$0.32
9.38%
Q3 • 25Beat
-
-$0.16
100.00%
Q4 • 25Beat
-$0.16
-$0.16
-
Q1 • 26Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$31.1M
$-10M
-32.12%
Q3 • 25
$23.2M
$-15M
-64.59%
Q1 • 26
-25.45%
49.93%
101.11%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$235M
$198M
84.36%
Q3 • 25
$225M
$205M
90.79%
Q1 • 26
-4.13%
3.18%
7.62%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
-
-
-
-
Q4 • 25
$4.7M
-
$-0.3M
$3.6M
Q1 • 26
-
-
NaN%
NaN%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Lifecore Biomedical Inc. share?
Collapse

Lifecore Biomedical Inc. shares are currently traded for undefined per share.

How many shares does Lifecore Biomedical Inc. have?
Collapse

Lifecore Biomedical Inc. currently has 37.5M shares.

Does Lifecore Biomedical Inc. pay dividends?
Collapse

No, Lifecore Biomedical Inc. doesn't pay dividends.

What is Lifecore Biomedical Inc. 52 week high?
Collapse

Lifecore Biomedical Inc. 52 week high is $8.98.

What is Lifecore Biomedical Inc. 52 week low?
Collapse

Lifecore Biomedical Inc. 52 week low is $3.63.

What is the 200-day moving average of Lifecore Biomedical Inc.?
Collapse

Lifecore Biomedical Inc. 200-day moving average is $6.92.

Who is Lifecore Biomedical Inc. CEO?
Collapse

The CEO of Lifecore Biomedical Inc. is Paul Josephs.

How many employees Lifecore Biomedical Inc. has?
Collapse

Lifecore Biomedical Inc. has 382 employees.

What is the market cap of Lifecore Biomedical Inc.?
Collapse

The market cap of Lifecore Biomedical Inc. is $180M.

What is the P/E of Lifecore Biomedical Inc.?
Collapse

The current P/E of Lifecore Biomedical Inc. is null.

What is the EPS of Lifecore Biomedical Inc.?
Collapse

The EPS of Lifecore Biomedical Inc. is -$1.27.

What is the PEG Ratio of Lifecore Biomedical Inc.?
Collapse

The PEG Ratio of Lifecore Biomedical Inc. is 2.66.

What do analysts say about Lifecore Biomedical Inc.?
Collapse

According to the analysts Lifecore Biomedical Inc. is considered a buy.